{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-053295","form_type":"8-K","ticker":"BJDX","cik":"0001704287","company_name":"Bluejay Diagnostics, Inc.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.772337+00:00","generated_at":"2026-05-14T21:52:23.500935+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Bluejay Diagnostics Q1 2026: net loss $1.9M, SYMON-II study at 680 of 750 patients","bullets":["Cash and equivalents $3.7M as of Mar 31, 2026; net loss $1.9M unchanged YoY.","SYMON-II pivotal study enrollment at ~680 patients toward target of 750.","Resolved manufacturing issues with Sanyoseiko; progressing toward analytical/clinical validation.","Continuing FDA 510(k) strategy for Symphony IL-6 test after validation activities."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-053295","json":"https://secwatch.observer/filing/0001213900-26-053295.json","markdown":"https://secwatch.observer/filing/0001213900-26-053295.md","text":"https://secwatch.observer/filing/0001213900-26-053295.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026053295/0001213900-26-053295-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026053295/ea0289580-8k_bluejay.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:52:23.500935+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dfc88f14560818f84c24528986c7d26e1900218a","claim":"Bluejay Diagnostics, Inc. reported fiscal quarter ended March 31, 2026 results: net income approximately $1.9 million.","evidence_excerpt":"As of March 31, 2026, Bluejay reported cash and cash equivalents of approximately $3.7 million. The Company reported a net loss of approximately $1.9 million for the first quarter of 2026, compared to approximately $1.9 million for the same period in 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026053295/0001213900-26-053295-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal quarter ended March 31, 2026"},{"label":"Net income","value":"approximately $1.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}